- Home
- KYNB vs VYNE Comparison
KYNB vs VYNE Comparison
Compare KYNB & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | VYNE |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | United States |
| Employees | 34 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 22.3M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | KYNB | VYNE |
|---|---|---|
| Price | $6.90 | $0.68 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.0K | ★ 249.0K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.32 | $0.29 |
| 52 Week High | $9.58 | $1.96 |
Technical Indicators
Market Signals| Indicator | KYNB | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 64.96 |
| Support Level | $6.73 | $0.56 |
| Resistance Level | $7.42 | $0.69 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 39.55 | 93.64 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.